Once the target is identified, the design and production of TCRm antibodies is an important next step in the development of antibody therapies. Besides relying on engineering technology, another key to the production of TCRm antibodies is the development of recombinant MHC technology methods, which are essential to achieve tailored antibody selection strategies.

As experts in the field of MHC, Creative BioMart offers design and production services for TCRm antibodies targeting pMHC, including not only recombinant development of MHC molecules for antibody screening, but also engineering services for antibody generation, allowing researchers to truly select antibodies with specificity and MHC restriction.

Reported MHC-specific TCRm Antibodies

Natural antibodies with TCR specificity are rare, so we rely on bioengineering techniques to design and manufacture mimetic antibodies. In order to make them broadly applicable, attention has been focused on targeting disease-associated peptides presented by widely expressed MHCI and MHCII molecules. In the table below is information on some of the currently reported MHCI and MHCII specific TCRm antibodies.

Table 1. TCRm antibody against pMHC (Høydahl L S, et al., 2019)

Antibody Production Services We Offer

Generation of specific TCRm antibodies is dependent on engineering techniques, and our technology platform offers our customers several methods for generating TCRm.

• Hybridoma Technology
  MHC-restricted TCRm antibodies are generated using immunized animals with recombinant antigens or cells expressing the desired antigen to generate antibody-secretable hybridomas, and by testing antibody specificity using purified recombinant pMHC proteins for immunization and in vitro screening using multiple protein variants.
• Phage Display Technology
  We isolate antibodies against MHC-like molecules by immunizing animals with target pMHC, then generating antibody phage display libraries, and purifying them by repeated panning with cells expressing specific MHC antigens.
• Recombinant MHC Development Technology
  We provide custom and variant screening, evaluation and validation of pMHC complexes for immunization and antibody high-throughput screening to drive continued development of TCRm antibodies.

Research and Therapeutic Applications

• As a research tool for specific MHC-related peptide presentation. It can be used as a reagent to detect and quantify peptide presentation in vitro, to quantify pMHC levels and the minimum number of T cells required for activation, to elucidate peptide presentation levels and the phenotypic characteristics of peptide-presenting cells at different stages of disease, and to provide new insights into disease mechanisms.
• As a therapeutic agent for disease. It specifically targets cells presenting disease-causing peptides, selectively kills cancer or virus-infected cells and targets antigen-presenting cells presenting their own peptides for the treatment of cancer or autoimmune diseases.

TCRm antibodies can be used as both a research tool and a diagnostic treatment. It can help to study T cell responses and also target specific epitopes for disease intervention. With our advanced engineering and experience training, Creative BioMart has a strong capability to manage and produce TCRm antibodies to help our customers achieve the desired level of specificity. Contact us to explore TCRm antibodies further.

References

• Xu Y, et al. "T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins." Antibody Therapeutics (2019), 2(1):22-32.
• Høydahl L S, et al. "Targeting the MHC Ligandome by Use of TCR-Like Antibodies." Antibodies (2019), 8(2):32.